Targeting YTHDF2/MDSCs to improve radiotherapy

Cell Chem Biol. 2023 Jul 20;30(7):703-705. doi: 10.1016/j.chembiol.2023.06.024.

Abstract

Immunosuppression contributes to tumor-radiotherapy failure, but the mechanism remains elusive. Wang et al.1 reported that ionizing radiation (IR) induces YTHDF2 expression in myeloid-derived suppressor cells (MDSCs) via an IR-YTHDF2-NF-κB circuit, which contributes to MDSC expansion/migration and treatment failure. Genetic depletion or pharmacological inhibition of YTHDF2 overcomes immunosuppression and improves radiotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, N.I.H., Extramural
  • Comment

MeSH terms

  • Humans
  • Myeloid-Derived Suppressor Cells* / metabolism
  • NF-kappa B / metabolism
  • Neoplasms* / metabolism
  • Neoplasms* / radiotherapy
  • RNA-Binding Proteins / metabolism

Substances

  • NF-kappa B
  • YTHDF2 protein, human
  • RNA-Binding Proteins